<DOC>
	<DOCNO>NCT02661893</DOCNO>
	<brief_summary>The purpose study assess effect single- multiple-dose rifampin single-dose pharmacokinetics JNJ-42847922 oral administration healthy male female participant .</brief_summary>
	<brief_title>A Drug Interaction Study Healthy Participants Assess Effect Rifampin Pharmacokinetics JNJ-42847922</brief_title>
	<detailed_description>This open-label , fixed-sequence , single-center , multiple-dose study 14 healthy adult . All participant receive single oral dose 40 milligram ( mg ) JNJ-42847922 3 separate occasion : Day 1 ( JNJ-42847922 alone ) , Day 5 ( JNJ-42847922 single dose rifampin ) , Day 12 ( JNJ-42847922 combination steady-state rifampin ) . A daily dose 600 mg ( 2 * 300 mg ) rifampin administer Day 5 Day 12 . Following JNJ-42847922 dosing , serial blood sample collect 48 hour evaluation plasma concentration JNJ-42847922 metabolite . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy men woman nonchildbearing potential 18 60 year age , inclusive ; body mass index ( BMI ) 18 30 kilogram ( kg ) /meter^2 , inclusive , body weight less 50 kg nonsmoker ( current past 60 day ) History current clinically significant medical illness Clinically significant abnormal value hematology , clinical chemistry , urinalysis Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , within 14 day first dose study drug schedule completion study Received know inhibitor cytochrome P450 ( CYP ) 3A4 CYP2C9 activity within 28 day period le 5 time drug halflife ; whichever long , first dose study drug schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42847922</keyword>
	<keyword>Rifampin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>